ARDX Ardelyx Inc.

-0.04  -2%
Previous Close 2.61
Open 2.63
Price To Book 1.13
Market Cap 159685742
Shares 62,134,530
Volume 51,507
Short Ratio
Av. Daily Volume 333,193

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date September 13, 2019.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 4Q 2019.
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth
  2. Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
  3. Ardelyx, Inc. (NASDAQ:ARDX) Is Trading At A 28.78% Discount
  4. Ardelyx Inc (ARDX): Are Hedge Funds Right About This Stock?
  5. What Type Of Shareholder Owns Ardelyx Inc’s (NASDAQ:ARDX)?
  6. Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
  7. Ardelyx: 3Q Earnings Snapshot
  8. Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
  9. Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
  10. Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
  11. Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
  12. How Does Investing In Ardelyx Inc (NASDAQ:ARDX) Impact Your Portfolio?
  13. Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
  14. Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
  15. Edited Transcript of ARDX earnings conference call or presentation 7-Aug-18 8:30pm GMT
  16. Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
  17. Ardelyx, Inc. to Host Earnings Call